

Alicja Alicja M Gruszka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4961615/publications.pdf>

Version: 2024-02-01

32
papers

943
citations

393982

19
h-index

454577

30
g-index

32
all docs

32
docs citations

32
times ranked

1426
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. <i>British Journal of Haematology</i> , 2003, 120, 759-764.	1.2	115
2	p53 abnormalities in splenic lymphoma with villous lymphocytes. <i>Blood</i> , 2001, 97, 3552-3558.	0.6	87
3	Delineation of the minimal region of loss at 13q14 in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 99-106.	1.5	64
4	Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice. <i>Journal of Clinical Investigation</i> , 2007, 117, 3696-707.	3.9	58
5	Wnt Signalling in Acute Myeloid Leukaemia. <i>Cells</i> , 2019, 8, 1403.	1.8	55
6	Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. <i>The Hematology Journal</i> , 2004, 5, 47-54.	2.0	47
7	Adhesion Deregulation in Acute Myeloid Leukaemia. <i>Cells</i> , 2019, 8, 66.	1.8	44
8	The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization. <i>British Journal of Haematology</i> , 2000, 110, 839-846.	1.2	38
9	Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. <i>Genes Chromosomes and Cancer</i> , 2003, 36, 57-69.	1.5	37
10	Isolated Bone Marrow Involvement in Diffuse Large B Cell Lymphoma: A Report of Three Cases with Review of Morphological, Immunophenotypic and Cytogenetic Findings. <i>Leukemia and Lymphoma</i> , 2004, 45, 769-775.	0.6	36
11	A narrow deletion of 7q is common to HCL, and SMZL, but not CLL. <i>European Journal of Haematology</i> , 2004, 72, 390-402.	1.1	35
12	A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. <i>Blood</i> , 2010, 116, 2096-2102.	0.6	35
13	Unusual case of leukemic mantle cell lymphoma with amplified CCND1/IGH fusion gene. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 206-212.	1.5	31
14	HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 844.	1.8	31
15	The self-association coiled-coil domain of PML is sufficient for the oncogenic conversion of the retinoic acid receptor (RAR) alpha. <i>Leukemia</i> , 2011, 25, 814-820.	3.3	30
16	Comparative expressed sequence hybridization studies of high-hyperdiploid childhood acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2004, 41, 191-202.	1.5	28
17	Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2005, 156, 122-128.	1.0	26
18	High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. <i>Blood</i> , 2002, 99, 2221-2227.	0.6	25

#	ARTICLE	IF	CITATIONS
19	Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation. <i>Leukemia</i> , 2010, 24, 429-437.	3.3	20
20	Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. <i>Chemotherapy</i> , 2018, 63, 238-245.	0.8	17
21	AML1/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem/progenitor cells. <i>Scientific Reports</i> , 2016, 6, 34957.	1.6	15
22	Nucleophosmin leukemogenic mutant activates Wnt signaling during zebrafish development. <i>Oncotarget</i> , 2016, 7, 55302-55312.	0.8	14
23	Has Drug Repurposing Fulfilled Its Promise in Acute Myeloid Leukaemia?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1892.	1.0	11
24	Understanding the molecular basis of acute myeloid leukemias: where are we now?. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 43-53.	0.7	9
25	Recombinant protein quality evaluation: proposal for a minimal information standard. <i>Standards in Genomic Sciences</i> , 2011, 5, 195-197.	1.5	8
26	The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients. <i>Leukemia</i> , 2012, 26, 159-162.	3.3	7
27	An unusual form of persistent polyclonal B lymphocytosis in an infant. <i>British Journal of Haematology</i> , 2000, 110, 430-433.	1.2	6
28	Consolidation with ⁹⁰ Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	0.6	6
29	A (musical) note on protein purification. <i>FASEB Journal</i> , 2010, 24, 6-6.	0.2	2
30	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma – a case report. <i>Scientific Reports</i> , 2015, 5, 14829.	1.6	2
31	A Novel Platform to Test In Vivo Single Gene Dependencies in t(8,21) and t(15,17) AML Confirms Zeb2 as Leukemia Target. <i>Cancers</i> , 2020, 12, 3768.	1.7	2
32	CAR T cells targeting options in the fight against multiple myeloma. <i>Panminerva Medica</i> , 2021, 63, 37-45.	0.2	2